问题 › 我们如何获得更多客户？ › 医疗机构
基于价值合同下的更多归属生命是一个结果。决策在于CFO或医疗主任能够负担得起重复哪条路径。 对医疗机构而言，这更难的原因是结构性的：在没有每例成本数据的情况下，已接受38,000例生命的 downside risk 来定价。因此任何可信的答案都必须将每例成本和支付方组合放在同一视图中，而这正是大多数内部分析停止的地方，因为两者存在于不同系统中。
基于价值合同下的更多归属生命是一个结果。决策在于CFO或医疗主任能够负担得起重复哪条路径。 对医疗机构而言，这更难的原因是结构性的：在没有每例成本数据的情况下，已接受38,000例生命的 downside risk 来定价。因此任何可信的答案都必须将每例成本和支付方组合放在同一视图中，而这正是大多数内部分析停止的地方，因为两者存在于不同系统中。
几乎每家机构都能说出几种扩大面板规模的方法，但很少能说出哪一种在扣除每例成本后能提高每位提供者的贡献。这才是实际约束：不是缺少战术，而是缺乏证据证明在支付方组合决定回报时该多做哪一种战术。
有效的框架是路线经济学。对每条可行路径——接触新归属生命、现有面板转介、价值合同伙伴、患者搜索、活动、渠道——计算获取一个归属生命要花多少钱，多久贡献能覆盖每例成本，以及规模扩大时每例成本是否会上升。
大多数路径过不了第三道测试。它们在小规模时有效，因为依赖医疗主任的网络或注意力，一旦资源耗尽就悄然停止。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 面板规模增长在医疗主任停止引荐时停止
✓ 每例成本未知或仅以支付方组合的汇总形式已知
✓ 每条获取新归属生命的渠道都在小规模尝试，没有一条经过充分测试
通常会让情况更糟的做法。 同时以低于必要规模的预算运行多条归属生命路线，结果每条都得不出结论，反而花费更高。
It is for you if you run or finance a healthcare provider and growth depends on one person's relationships. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗机构. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Protect and grow the 34% operating-income ASC engine by replacing retiring surgeons and steering 212k attributed lives to the ASC within 24 months.
| Investment required | $3.0-4.0M total over 24 months ($1.8-2.2M surgeon succession + retention bonuses; $1.2-1.8M referral-optimization platform and analytics) |
| Expected return | Incremental $4.8-6.4M annual ASC contribution margin by Month 24; payback 14-18 months on $3.0-4.0M investment; lifts group operating margin from 4.2% to 5.8-6.4%. |
| Revenue, year 1 | $202-208M (ASC case volume +4-6%) |
| Revenue, year 2 | $212-220M (ASC case volume +6-8%; physician retention +2-3%) |
| Revenue, year 3 | $225-235M (ASC contribution ≥40% of operating income) |
| Exit criteria | Strategy abandoned if, by Month 12, fewer than two qualified orthopaedic surgeon candidates have signed LOIs OR if ASC case volume has not grown at least 2% YoY; in either case, board must decide within 30 days whether to pivot to hospital-system sale process at 8-10× EBITDA. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For 医疗机构 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
买方已经在那里、且能在你能融资的周期内收回获客成本的渠道。这是具体到业务的答案，通用答案价值很小。
先运行一个能奏效的，再加第二个。以四分之一必要预算同时运行四个渠道，只会得到四个无结论的结果，并让人相信什么都不管用。
你的销售周期加上一个回款周期，配合足够体积以区分结果与噪音。提前设定这个数字，才能避免决策被最会说服的人左右。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית